Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Fundamental Analysis
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) shows weak financial fundamentals with a PE ratio of 55.68, profit margin of 1.59%, and ROE of 0.69%. The company generates $5.3B in annual revenue with weak year-over-year growth of -3.03%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 28.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SHEZF's fundamental strength across five key dimensions:
Efficiency Score
WeakSHEZF struggles to generate sufficient returns from assets.
Valuation Score
ModerateSHEZF shows balanced valuation metrics.
Growth Score
WeakSHEZF faces weak or negative growth trends.
Financial Health Score
ExcellentSHEZF maintains a strong and stable balance sheet.
Profitability Score
ModerateSHEZF maintains healthy but balanced margins.
Key Financial Metrics
Is SHEZF Expensive or Cheap?
P/E Ratio
SHEZF trades at 55.68 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SHEZF's PEG of 0.08 indicates potential undervaluation.
Price to Book
The market values Shenzhen Hepalink Pharmaceutical Group Co., Ltd. at 0.39 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 23.11 times EBITDA. This signals the market has high growth expectations.
How Well Does SHEZF Make Money?
Net Profit Margin
For every $100 in sales, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. keeps $1.59 as profit after all expenses.
Operating Margin
Core operations generate 1.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.69 in profit for every $100 of shareholder equity.
ROA
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generates $0.51 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. produces operating cash flow of $1.32B, showing steady but balanced cash generation.
Free Cash Flow
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generates strong free cash flow of $1.55B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.06 in free cash annually.
FCF Yield
SHEZF converts 33.06% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
55.68
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.007
vs 25 benchmark
ROA
Return on assets percentage
0.005
vs 25 benchmark
ROCE
Return on capital employed
0.007
vs 25 benchmark
How SHEZF Stacks Against Its Sector Peers
| Metric | SHEZF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 55.68 | 29.02 | Worse (Expensive) |
| ROE | 0.69% | 745.00% | Weak |
| Net Margin | 1.59% | -46183.00% (disorted) | Weak |
| Debt/Equity | 0.18 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 2.31 | 4.52 | Strong Liquidity |
| ROA | 0.51% | -17797.00% (disorted) | Weak |
SHEZF outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-2.94%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-48.11%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
919.42%
Industry Style: Defensive, Growth, Innovation
High Growth